---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-011799"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T09:48:47.681720+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytoDyn CEO resigns, returns as SVP; files $100M+ claim against former CRO Amarex

## Summary
- Dr. Cyrus Arman resigned as President and PEO on July 6, 2023; returns as SVP Business Operations with reduced salary of $300k.
- Antonio Migliarese continues as Interim President and CFO; board has begun search for new President/CEO.
- CytoDyn filed supplemental Statement of Claim against Amarex seeking damages exceeding $100M for alleged breach of CRO services.
- Under new agreement, Arman forfeited RSUs/PSUs; option to purchase 1,575,557 shares vests 40% immediately, rest over 6 months.

## SEC filing metadata
- accession: 0001558370-23-011799
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837023011799/0001558370-23-011799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837023011799/cydy-20230706x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-011799
- JSON: https://secwatch.observer/filing/0001558370-23-011799.json
- Plain text: https://secwatch.observer/filing/0001558370-23-011799.txt

## Key facts
- Executive change
  Cyrus Arman was appointed as Senior Vice President, Business Operations at CytoDyn Inc..
  - Action: appointed
  - Role: Senior Vice President, Business Operations
  source text: Dr. Cyrus Arman, on medical leave since May 18, 2023, after serving as the President and principal executive officer of CytoDyn Inc. (the “Company”) since July 9, 2022, resigned as the Company’s President and principal executive officer on July 6, 2023, and returned to the Company as its Senior Vice President, Business Operations, a nonexecutive position in which he will work reduced hours, effective July 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023011799/0001558370-23-011799-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.